BV is an effective alternative to bleomycin, rituximab may enhance efficacy but increases infectious risk, and PD-1 inhibitors, while highly active in HL, require careful selection and monitoring in immunodeficient patients. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.